Peel Hunt reissued their buy rating on shares of Clinigen Group PLC (LON:CLIN) in a research note issued to investors on Wednesday morning. Peel Hunt currently has a GBX 1,000 ($13.05) price target on the stock.
A number of other research firms have also commented on CLIN. Stifel Nicolaus reaffirmed a buy rating and set a GBX 800 ($10.44) price target on shares of Clinigen Group PLC in a research report on Wednesday, July 20th. Numis Securities Ltd reaffirmed a buy rating and set a GBX 916 ($11.96) price target on shares of Clinigen Group PLC in a research report on Wednesday, July 20th. Five analysts have rated the stock with a buy rating, Clinigen Group PLC presently has a consensus rating of Buy and an average price target of GBX 856.60 ($11.18).
Clinigen Group PLC (LON:CLIN) opened at 732.60999 on Wednesday. Clinigen Group PLC has a 12-month low of GBX 492.75 and a 12-month high of GBX 739.50. The company’s market cap is GBX 839.56 million. The stock has a 50 day moving average price of GBX 655.62 and a 200-day moving average price of GBX 599.30.
The company also recently announced a dividend, which will be paid on Friday, November 25th. Shareholders of record on Thursday, November 3rd will be issued a dividend of GBX 2.70 ($0.04) per share. This is an increase from Clinigen Group PLC’s previous dividend of $1.30. The ex-dividend date is Thursday, November 3rd. This represents a dividend yield of 0.38%.
About Clinigen Group PLC
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.